effectiveness of SRT in specifically treating this disease has not been widely reported. We have prospectively gathered data on 12 patients treated with SRT for uncontrolled acromegaly and report on the effectiveness of this treatment in terms of biochemical and radiological responses.
SUBJECTS AND METHODS

Subjects
The study protocol was approved by the Capital Health Research Ethics Board. All patient data for those treated with SRT were collected prospectively and entered into the Halifax Neuropituitary Program's database. From this database, we identified all patients who were treated for surgically incurable and medically refractory acromegaly by SRT, and who had a minimum follow-up of six months, for inclusion in the study. The diagnosis of acromegaly was based on the presence of typical clinical features of excessive GH production, elevated serum IGF-1 levels compared with age and gender matched normal values, and non-suppression of GH to < 1µg/L after an oral glucose tolerance test. The primary indication for SRT in all patients was the lack of biochemical control that was confirmed by demonstrating persistent elevation of age and sex adjusted IGF-1, despite previous surgery and/or medical therapy. Ten patients had previously undergone transsphenoidal pituitary surgery for GH producing macroadenomas and still had residual pituitary adenomatous tissue, while the remaining two patients had received pharmacologic treatment only. All patients underwent a neurosurgical evaluation and were felt not to be surgical candidates, because either surgery was not acceptable by the patient or it was felt that surgery would have a low probability of cure.
SRT Treatment
All patients were treated using the BrainLAB micro-multileaf collimator fitted on a Varian 600C linear accelerator. Planning was carried out using BrainSCAN 5.2 treatment planning software (©1989/2002 by BrainLAB AG) and later using BrainSCAN 5.31 (©1989/2004 by BrainLAB AG). Prior to treatment, patients were fitted with a customized aquaplast mask for the BrainLAB re-locatable head frame, which allowed stereotactic imaging and provided immobilization of the head. Previous work from our centre has documented precision of isocentre targeting during fractionated treatment using this apparatus 5 . A stereotactic non-contrast planning CT scan was carried out with axial slices at 1 mm intervals obtained at the level of the pituitary adenoma. The rest of the brain and skull was scanned with 3 mm axial slices. Each patient had a gadolinium enhanced MRI scan (Seimens 1.5T: 3D MP RAGE 1.25 mm sagittal slices and T1W 3.0 mm slices in axial and coronal planes post-gadolinium) which was fused with the planning CT scan in an automated fashion.
The adenoma, as well as adjacent dose-limiting critical structures such as the optic nerves, chiasm, eyes and brainstem, were contoured ( Figure 1 ). No margin was added to the adenoma, such that the planning target volume was equal to the clinical target volume. Individual treatment plans were generated, typically using 8-15 non-coplanar static conformal 6 MV photon beams. Radiation dose was prescribed to the tumour margin at the 80% isodose line in all patients. The prescription dose was 5,000 cGy in 25 fractions in 11 patients; in one patient where a small residual adenoma was located far from the optic chiasm, 2,500 cGy were delivered in five fractions. Medical therapy was not stopped during SRT. Patients were seen weekly during SRT by their attending radiation oncologist. 
FOLLOW-UP PROTOCOL
A radiation oncologist contacted all patients by phone one month after treatment was completed to monitor for acute and early subacute toxicity. Patients were then seen in a multidisciplinary clinic by the neurosurgeon, endocrinologist and radiation oncologist three to six months after the SRT treatment. Thereafter, they were followed every six months for two years and then annually. At each of these clinic visits, patients underwent a careful clinical evaluation, Goldmann visual field testing (all performed at the same centre and interpreted by a single ophthalmologist), MRI of sella (with and without gadolinium enhancement), and 0800 h blood sample testing that included serum IGF-1, GH, cortisol, luteinizing hormone (LH), follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), free thyroxine (T4), total testosterone, estradiol, prolactin, and electrolytes. The pharmacologic therapy was gradually reduced or withdrawn in patients who achieved and maintained normal IGF-1. Biochemical remission was defined as achieving both normal IGF-1 as well as GH < 2.5µg/L, with or without pharmacologic therapy. For those patients who were unable to maintain normal IGF-1, the minimum effective dose of pharmacologic therapy was maintained. Assays for cortisol, prolactin, FSH, LH, TSH and T4 were performed routinely by immunoassays with chemiluminescent detection using an ADVIA Centaur system (Bayer HealthCare, Tarrytown, NY). Growth hormone and IGF-1 were similarly measured using the Immulite 2000 system (Diagnostics Products Corporation, Los Angeles, CA).
Tumour Volume
The pituitary adenoma volumes were calculated by the treatment planning software prior to SRT treatment according to the contoured planning target volume. Subsequently, the most recent follow-up MRI scan on each patient was imported into the treatment planning software and the residual tumour was again contoured such that comparative analysis could be performed.
Statistical analysis
The baseline pre-SRT treatment serum levels of hormones (µg/L) were compared with levels taken at subsequent patient follow-up visits. Baseline pre-SRT treatment tumour volumes (cc) were compared with measures taken at the last patient follow-up evaluation. Results of these nonparametric median values were compared using the Wilcoxon Signed Ranks Test (SPSS, v14).
RESULTS
Between 2003 and 2006, a total of 12 patients were treated by SRT for uncontrolled acromegaly. Baseline clinical and demographic characteristics of all patients are shown in Table 1 . The median age of patients was 50.5 years; 9 of 12 patients were female. All patients except #7 and #10 had previously undergone transsphenoidal surgery for pituitary GH producing adenoma, and had at least six months of medical therapy prior to SRT. Patients #3 and #5 were on dopamine agonist therapy alone whereas the remainder were on somatostatin analogue (SA) therapy. Prior to SRT, all but two patients had normal pituitary function (one with secondary hypogonadism and another with secondary hypothyroidism, both requiring replacement therapy). Stereotactic radiation therapy was tolerated without significant difficulty in all cases; no patient required a treatment break or interruption. The median follow-up following SRT was 28.5 months (range: 6 -41 months). No patients were lost to follow-up.
HORMONAL PROFILE
Changes in GH and IGF-1 levels are presented in Table 2 
Tumour Size
The MRI images pre-and post-SRT treatment are shown in Figure 3 . The data regarding tumour volume are summarized in Table 3 . The mean tumour volumes before and after SRT were 1.56 cc and 0.96 cc, respectively. The mean tumour volume was reduced by 0.60 cc (40%) (p = 0.005).
Visual Field Testing
No patient had a new visual field defect at most recent testing. Transient changes on Goldmann visual field testing were noted at six months in Patients #4 and #8, and at 24 months in Patient #5, most often consisting of a transient superior depression and not correlating with any detectable changes on MRI. In Patient #1, there was an unexplainable improvement in the pre-SRT visual field abnormality.
DISCUSSION
The criteria for remission in acromegaly patients have changed over the years. The currently employed criteria are based on consensus and include achieving basal GH of < 2.5 µg/L, normal age-gender matched IGF-1, and GH suppressibility to < 1 µg/L after an oral glucose load 6 . Both microsurgical tumour resection and medical therapy are regarded as effective first line treatments. In experienced hands, patients with microadenomas can expect a cure rate of > 80% 7, 8 . However, given the fact that over 70% patients with acromegaly have macroadenomas, the cure rate in this patient population with surgery alone is < 50% 9 . These surgically incurable cases have traditionally received further treatment with either pharmacologic or radiation therapy. The main disadvantages of pharmacologic therapy are the need for life-long treatment, high cost and the lack of effectiveness in biochemical and tumour control. Of the currently available choices, dopaminergic agonists (bromocriptine and cabergoline) have been reported to lower IGF-1 in 10-30% 10,11 whereas the SA (octreotide and lanreotide) may achieve biochemical control in 50-60% of cases 12 . The recently available GH receptor antagonist, pegvisomant, achieves biochemical control in 90% of patients 13 but is also the most expensive, lacks long-term safety data, and does not act to control tumour growth 14 . The role of radiation in uncontrolled acromegaly has been controversial and reflects the development of modern radiation delivery techniques. While some studies have proposed a definite role for conventional radiotherapy (RT) 15, 16 , others have reported a lack of efficacy 17, 18 . Conventional RT has also been linked to a high incidence of side effects such as hypopituitarism, cerebral tissue necrosis, neurophysiological impairment, damage to the optic pathways and even development of secondary tumours [19] [20] [21] [22] . Although direct comparison with previously published studies is unfeasible because of outdated criteria for cure [23] [24] [25] [26] , the reported rate of normalization of IGF-1 after conventional RT using more stringent modern criteria is no higher than 60-70% at ten years 16, 27 . The success of SRS in treating patients with acromegaly, and employing current criteria for cure, has been variable with reported cure rates ranging from 43%-82% 28, 29 . In those patients where IGF-1 values have normalized, the mean time to IGF-1 normalization has been reported as two years 30 . Another recent study, where patients were tested with SRS despite the article's title suggesting treatment by SRT, reported remission rates of 30.5% at three years and 52.6% at five years 3 . The role of SRT in the management of pituitary adenomas has recently been reported in another study 31 ; however, only two of the reported 14 patients had GH-producing adenomas. In our study, 50% of patients achieved normal or near-normal IGF-1 over a median duration of 28.5 months (range 8 -41 months), early results that compare favourably with SRS. Furthermore, seven of eight patients with pre-treatment basal GH > 2.5 ug/L achieved target basal GH. One patient discontinued, while another two were able to reduce, the dosage of their SA therapy. During the SRT treatment, most of our patients (10 of 12) were maintained on SA therapy. Although it has been suggested by some that SA therapy may confer a radioprotective effect, thereby reducing the efficacy of radiation therapy 32, 33 , others have not found such an effect 3, 15, 34 . In our study, both patients who were not on SA therapy achieved normal IGF-1, whereas four of ten who were on SA therapy achieved biochemical remission. Due to the limited sample size, we were unable to compare the two groups.
The proposed benefit of modern radiotherapy delivery systems, including SRT, over conventional RT is relative radiation sparing of the adjacent tissue. Consistent with this, no patient in our series reported any enduring symptoms or signs suggestive of local neurologic injury. One patient developed an additional pituitary hormone abnormality (secondary hypoadrenalism) at 24 months; longer term follow-up may see this incidence increase. New visual field abnormalities, defined strictly as any change found in Goldman visual field testing were observed in three patients. All of these new visual fields abnormalities were subclinical and resolved spontaneously without treatment. Furthermore, the defects were not consistently in the part of the visual field most likely to be affected by the radiation treatment, indicating that these new visual field abnormalities may simply reflect test-to-test variation. However, despite these encouraging early data, longer follow-up of these patients is required to determine the continuing safety of SRT and its effect on pituitary function and vision.
The current study is the first to report the outcome of a series of acromegaly patients treated with SRT. Our early results indicate that 50% of these patients will achieve biochemical remission, with or without the need for concomitant pharmacologic therapy, at 28.5 months. It remains to be seen whether longer follow-up of these patients will result in larger numbers of cures and larger numbers of patients being able to reduce or discontinue SA therapy. Although the primary treatment of acromegaly remains surgical, these results indicate that in carefully selected patients SRT is a treatment modality that should be considered in managing patients with uncontrolled acromegaly.
